annual CFO:
-$142.77M+$117.60M(+45.17%)Summary
- As of today (September 16, 2025), CRSP annual cash flow from operations is -$142.77 million, with the most recent change of +$117.60 million (+45.17%) on December 31, 2024.
- During the last 3 years, CRSP annual CFO has fallen by -$681.75 million (-126.49%).
- CRSP annual CFO is now -126.49% below its all-time high of $538.97 million, reached on December 31, 2021.
Performance
CRSP Cash from operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFO:
-$113.88M-$59.93M(-111.10%)Summary
- As of today (September 16, 2025), CRSP quarterly cash flow from operations is -$113.88 million, with the most recent change of -$59.93 million (-111.10%) on June 30, 2025.
- Over the past year, CRSP quarterly CFO has dropped by -$18.30 million (-19.14%).
- CRSP quarterly CFO is now -114.11% below its all-time high of $807.00 million, reached on June 30, 2021.
Performance
CRSP quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFO:
-$324.77M-$18.30M(-5.97%)Summary
- As of today (September 16, 2025), CRSP TTM cash flow from operations is -$324.77 million, with the most recent change of -$18.30 million (-5.97%) on June 30, 2025.
- Over the past year, CRSP TTM CFO has dropped by -$203.01 million (-166.73%).
- CRSP TTM CFO is now -159.11% below its all-time high of $549.43 million, reached on June 30, 2021.
Performance
CRSP TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
CRSP Cash from operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +45.2% | -19.1% | -166.7% |
| 3 y3 years | -126.5% | +19.8% | +26.9% |
| 5 y5 years | -351.9% | -288.9% | -686.8% |
CRSP Cash from operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -126.5% | +71.2% | -203.8% | +19.8% | -166.7% | +34.5% |
| 5 y | 5-year | -126.5% | +71.2% | -114.1% | +19.8% | -159.1% | +34.5% |
| alltime | all time | -126.5% | +71.2% | -114.1% | +19.8% | -159.1% | +34.5% |
CRSP Cash from operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$113.88M(+111.1%) | -$324.77M(+6.0%) |
| Mar 2025 | - | -$53.95M(+7.8%) | -$306.47M(+114.7%) |
| Dec 2024 | -$142.77M(-45.2%) | -$50.03M(-53.2%) | -$142.77M(-24.4%) |
| Sep 2024 | - | -$106.91M(+11.9%) | -$188.82M(+55.1%) |
| Jun 2024 | - | -$95.58M(-187.1%) | -$121.76M(-23.6%) |
| Mar 2024 | - | $109.75M(-214.2%) | -$159.42M(-38.8%) |
| Dec 2023 | -$260.38M(-47.5%) | -$96.07M(+141.1%) | -$260.38M(-6.2%) |
| Sep 2023 | - | -$39.86M(-70.1%) | -$277.63M(-19.1%) |
| Jun 2023 | - | -$133.25M(-1614.3%) | -$342.99M(-2.5%) |
| Mar 2023 | - | $8.80M(-107.8%) | -$351.70M(-29.1%) |
| Dec 2022 | -$495.74M(-192.0%) | -$113.33M(+7.7%) | -$495.74M(+5.8%) |
| Sep 2022 | - | -$105.22M(-25.9%) | -$468.45M(+5.4%) |
| Jun 2022 | - | -$141.96M(+5.0%) | -$444.56M(-188.1%) |
| Mar 2022 | - | -$135.24M(+57.2%) | $504.40M(-6.4%) |
| Dec 2021 | $538.97M(-326.1%) | -$86.04M(+5.8%) | $538.97M(-0.9%) |
| Sep 2021 | - | -$81.33M(-110.1%) | $543.80M(-1.0%) |
| Jun 2021 | - | $807.00M(-901.7%) | $549.43M(-291.5%) |
| Mar 2021 | - | -$100.66M(+24.0%) | -$286.85M(+20.3%) |
| Dec 2020 | -$238.37M | -$81.21M(+7.3%) | -$238.37M(+55.0%) |
| Sep 2020 | - | -$75.70M(+158.5%) | -$153.78M(-377.9%) |
| Jun 2020 | - | -$29.28M(-43.9%) | $55.34M(+14.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | -$52.17M(-1645.5%) | $48.24M(-14.9%) |
| Dec 2019 | $56.68M(-158.9%) | $3.38M(-97.5%) | $56.68M(+127.4%) |
| Sep 2019 | - | $133.42M(-466.7%) | $24.93M(-119.4%) |
| Jun 2019 | - | -$36.38M(-16.8%) | -$128.46M(+9.5%) |
| Mar 2019 | - | -$43.74M(+54.2%) | -$117.29M(+21.9%) |
| Dec 2018 | -$96.24M(+37.3%) | -$28.37M(+42.1%) | -$96.24M(+16.4%) |
| Sep 2018 | - | -$19.96M(-20.8%) | -$82.71M(+5.2%) |
| Jun 2018 | - | -$25.21M(+11.1%) | -$78.61M(+13.3%) |
| Mar 2018 | - | -$22.69M(+52.9%) | -$69.37M(-1.0%) |
| Dec 2017 | -$70.09M(+32.6%) | -$14.84M(-6.5%) | -$70.09M(-9.1%) |
| Sep 2017 | - | -$15.87M(-0.7%) | -$77.12M(+8.5%) |
| Jun 2017 | - | -$15.97M(-31.8%) | -$71.08M(+3.4%) |
| Mar 2017 | - | -$23.41M(+7.1%) | -$68.71M(+24.2%) |
| Dec 2016 | -$52.86M(-188.9%) | -$21.87M(+122.6%) | -$55.31M(+65.4%) |
| Sep 2016 | - | -$9.82M(-27.8%) | -$33.44M(+41.6%) |
| Jun 2016 | - | -$13.60M(+35.8%) | -$23.62M(+86.1%) |
| Mar 2016 | - | -$10.01M(+273.7%) | -$12.69M(+197.8%) |
| Dec 2015 | $59.43M(-1339.9%) | - | - |
| Jun 2015 | - | -$2.68M(+69.3%) | -$4.26M(+169.3%) |
| Mar 2015 | - | -$1.58M | -$1.58M |
| Dec 2014 | -$4.79M | - | - |
FAQ
- What is CRISPR Therapeutics AG annual cash flow from operations?
- What is the all time high annual CFO for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG annual CFO year-on-year change?
- What is CRISPR Therapeutics AG quarterly cash flow from operations?
- What is the all time high quarterly CFO for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG quarterly CFO year-on-year change?
- What is CRISPR Therapeutics AG TTM cash flow from operations?
- What is the all time high TTM CFO for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG TTM CFO year-on-year change?
What is CRISPR Therapeutics AG annual cash flow from operations?
The current annual CFO of CRSP is -$142.77M
What is the all time high annual CFO for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high annual cash flow from operations is $538.97M
What is CRISPR Therapeutics AG annual CFO year-on-year change?
Over the past year, CRSP annual cash flow from operations has changed by +$117.60M (+45.17%)
What is CRISPR Therapeutics AG quarterly cash flow from operations?
The current quarterly CFO of CRSP is -$113.88M
What is the all time high quarterly CFO for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high quarterly cash flow from operations is $807.00M
What is CRISPR Therapeutics AG quarterly CFO year-on-year change?
Over the past year, CRSP quarterly cash flow from operations has changed by -$18.30M (-19.14%)
What is CRISPR Therapeutics AG TTM cash flow from operations?
The current TTM CFO of CRSP is -$324.77M
What is the all time high TTM CFO for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high TTM cash flow from operations is $549.43M
What is CRISPR Therapeutics AG TTM CFO year-on-year change?
Over the past year, CRSP TTM cash flow from operations has changed by -$203.01M (-166.73%)